NCT03091439View on ClinicalTrials.gov

Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Osteomyelitis
Interventions
DRUG

Dalbavancin

Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.

DRUG

Standard of Care

Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.

Trial Locations (1)

34982

Midway Immunology and Research Center, Ft. Pierce

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03091439 - Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis | Biotech Hunter | Biotech Hunter